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Summary. Background: Post-thrombotic syndrome (PTS) is a
chronic complicationof deep vein thrombosis (DVT)affecting a
large number of patients. Because of its potential debilitating
effects, identificationof patients at high risk for thedevelopment
of this syndrome is relevant, and only a few predictors are
known. Objectives: To assess the incidence and potential
predictors of PTS. Methods: We prospectively followed 111
consecutive patients for 2 years after a first episode of
objectively documented DVT of the leg. With non-invasive
venous examinations, residual thrombosis, valvular reflux, calf
muscle pump function and venous outflow resistance were
assessed at 6 weeks, 3 months, 6 months, 1 year, and 2 years.
The Clinical, Etiologic, Anatomic, and Pathophysiologi classi-
fication was used to record the occurrence and severity of PTS.
Regression analysis with area under the receiver operating
characteristic (ROC) curve was performed to identify potential
predictors. Results: The cumulative incidence of PTS was 46%
after 3 months, and the incidence and severity did not increase
further.Men appeared to be at increased risk as compared with
women (risk ratio [RR] 1.4, 95% confidence interval [CI] 0.9–
2.2), as were patients over 50 years as compared with younger
patients (RR 1.4%, 95% CI 0.9–2.1). Patientswith thrombosis
localized in theproximal veins at diagnosis hadan increased risk
of PTS as compared with patients with distal thrombosis
(RR 2.3%, 95% CI 1.0–5.6). PTS developed in 32 of 52
patients (62%) with residual thrombosis in the proximal veins
6 weeks after diagnosis, as compared with 17 of 45 patients
(38%) without residual proximal thrombosis, leading to a 1.6-
fold increased risk (95% CI 1.0–2.5). The presence of valvular
reflux in the superficial veins was also a predictor at 6 weeks,
with a 1.6-fold increased risk as comparedwith patientswithout
superficial reflux (95% CI 1.1–2.3). A multivariate analysis of
these predictors yielded an area under the ROC curve of 0.72
(95% CI 0.62–0.82). Conclusions: PTS develops in half of all
patientswithin 3 months,with no further increase being seenup
to 2 years of follow-up. Male sex, age over 50 years, proximal
localization of the thrombus at entry, residual proximal
thrombosis and superficial valvular reflux at 6 weeks seem to
be the most important predictors of PTS in patients with a first
episode of DVT. Duplex scanning 6 weeks after diagnosis
appears to be clinically useful for the identification of patients at
risk of PTS.
Keywords: deep vein thrombosis, non-invasive venous exami-
nation, post-thrombotic syndrome, predictors.
Introduction
Acute deep vein thrombosis (DVT) may lead to chronic
venous complications in one of every two to three patients [1].
Factors that play a role in the pathophysiology of this
so-called post-thrombotic syndrome (PTS) are: (i) damage to
venous valves, which causes valvular reflux with diminished
calf muscle pump function; and (ii) persistent venous obstruc-
tion resulting from incomplete thrombus clearance. This leads
to high walking venous pressure, resulting in alterations of the
skin microcirculation and morphologic skin changes [2]. These
changes can be classified with the clinical score of the Clinical,
Etiologic, Anatomic, and Pathophysiologic (CEAP) classifi-
cation [3,4].
As PTS reduces quality of life [5], and is costly to society [6],
it would be desirable to identify patients at risk for PTS at an
early stage. Strategies for the prevention and management of
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PTS should be applied in these high-risk patients. Recurrent
ipsilateral DVT is a risk factor, and should be prevented with
adequate anticoagulation therapy [7,8]. Continuous use of
elastic compression therapy after DVT reduces the risk of PTS
by approximately 50% [8,9]. Non-invasive venous examina-
tions, such as duplex scanning and strain gauge plethysmog-
raphy, may be useful to predict the development of PTS. With
duplex scanning, it is possible to measure the extent of the
initial thrombus, residual thrombosis, and valvular reflux;
strain gauge plethysmography quantifies venous outflow
resistance and calf muscle pump function [10–13]. However,
these non-invasive examinations are not routinely applied in
clinical practice. Factors that have been associated with the
development of PTS are male sex, advanced age, increased
body mass index, idiopathic DVT, proximal localization of
DVT, extent of residual vein thrombosis, presence of valvular
reflux, reduced calf muscle pump function, and increased
venous outflow resistance [14–25]. However, the results of
previous studies are in conflict with regard to the predictive
value of these factors.
The objectives of the present study were to assess the
incidence of PTS during 2 years of follow-upwith standardized
compression treatment after a first episode of DVT, and to
determine the predictive value of non-invasive venous exam-
ination for the development of PTS.
Methods
Study design
Between May 2002 and September 2005, consecutive patients
aged 18–70 years with a first episode of DVT of the leg seen at
the Meander Medical Center (Amersfoort, The Netherlands)
were included in this follow-up study. All patients participated
in the multicenter Multiple Environmental and Genetic
Assessment (MEGA) of risk factors for venous thrombosis
study [24,26]. Patients with a life-expectancy of< 1 year (eight
patients) and those unable to undergo ambulant compression
therapy (one patient) were excluded from the current study.
Among the 134 eligible patients, 23 refused to participate,
leaving 111 participating patients.
All patients were treated according to a standardized
protocol with low molecular weight heparin and vitamin K
antagonists for 6 months. Short-stretch elastic bandages were
applied immediately after diagnosis. As soon as edema was
reduced, elastic therapeutic stockings were prescribed with
compression class III (ankle pressure 35–45 mmHg). The
lengths of the bandages and the elastic therapeutic stockings
were dependent on the localization of the thrombus. In cases of
proximal DVT, thigh-length bandages and stockings were
applied for 3 months, followed by knee-length elastic com-
pression stockings. In patients with distal DVT, knee-length
bandages and stockings only were applied. Elastic compression
stockings were adapted for each patient by an experienced
professional bandagist. Patients were instructed and motivated
to wear the elastic compression stockings for at least 2 years.
At each visit, details on the frequency and duration of use of
elastic compression stockings were recorded.
Patients filled in a detailed questionnaire on demographic
variables and acquired risk factors for venous thrombosis. The
questionnaire covered the period of 1 year prior to the
thrombotic event. DVT was defined as idiopathic in the
absence of malignancy, surgery, plaster cast, minor injury,
being bedridden for four consecutive days or more at home or
in the hospital in the 3 months prior to the thrombosis,
pregnancy, and the use of female hormones. Body mass index
was calculated from self-reported weight and height (kg m)2).
All patients underwent physical examinations of the leg and
non-invasive venous examinations at regular intervals. These
non-invasive venous tests consisted of duplex scanning and
strain gauge plethysmography. These tests were performed at
the time of diagnosis of DVT, after 6 weeks, 3 months,
6 months, 1 year and 2 years, or when recurrent venous
thrombosis occurred. Symptomatic recurrent DVT was objec-
tively confirmed with duplex scanning.
A dermatologist who was unaware of the findings of non-
invasive venous tests performed the physical examinations of
the leg and classified the skin changes in patients according to
the clinical score of the CEAP classification [3,4]. In this
classification, class 0 represents no visible or palpable signs of
PTS; class 1 represents telangiectasies or reticular veins; class 2
represents varicose veins; class 3 represents edema without skin
changes; class 4 represents skin changes ascribed to venous
disease (pigmentation, venous eczema, lipodermatosclerosis,
white atrophy, and corona phlebectatica); class 5 represents
skin changes with healed venous ulcer; and class 6 represents
skin changes with active venous ulcer. PTS was considered to
be present if the score was 3 or more. The presence and severity
of PTS was assessed in the leg in which the DVT occurred. The
assessor did not have access to scores obtained on previous
study visits.
Duplex scanning was performed by one of three experienced
vascular technologists with a Philips iU22 scanner (Philips
Healthcare, Best, the Netherlands) with a 5–12-MHz linear
array probe. Seventeen vein segments were examined, with the
patient in a 45 sitting position [10]. The common femoral vein,
superficial femoral vein, long and short saphenous veins,
popliteal vein, posterior and anterior tibial veins, peroneal vein
and gastrocnemial vein were examined. In the calf, a distinction
was made between the superficial and the deeper vein.
Compressibility was assessed in the transverse plane. A vein
was considered to be non-compressible when it was not
completely compressed under gentle pressure of the duplex
probe. A thrombosis score was based on the extent of occlusion
by the thrombus [3]. A vein segment scored 1 point when it was
occluded completely or in part. A fully patent vein segment
showed complete compressibility and flow, and scored zero
points. Thrombosis score values for each patient were calcu-
lated by adding the thrombosis score values of each of the 17
vein segments. The thrombosis score was separately scored for
the five proximal deep vein segments (common femoral,
superficial femoral [proximal, middle, and distal] and popliteal
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veins), the eight distal deep vein segments (two posterior tibial,
two anterior tibial, two peroneal, and two gastrocnemial), and
the four superficial vein segments (long saphenous vein
[proximal, middle, and distal] and short saphenous).
In the longitudinal plane, the presence of venous flow and
valvular reflux was measured by duplex examination. Patho-
logic valvular reflux was defined as a reversed flow duration of
more than 1 s in the proximal veins and more than 0.5 s in the
distal veins. Reflux score values were calculated by adding the
number of vein segments with pathologic valvular reflux [10].
Calf muscle pump function and venous outflow resistance
were measured with a Filtrass angio strain gauge plethysmo-
graph (Compumedics, Singen, Germany) [11–13]. Patients
were examined in the supine position with the knees slightly
bent at an angle of 90 and pneumatic cuffs around the thighs,
and strain gauges around the calves. The cuffs were inflated
with a cuff pressure of 50 mmHg, which resulted in an increase
in venous volume and pressure. Maximum volume was
achieved when the venous pressure equaled the effective
congestion pressure. Then, with the cuffs still inflated, the
patient was instructed to perform 10 dorsal extensions. The calf
muscle pump action resulted in a volume decrease in the limb.
In the period of rest after the exercise, with the cuffs still
inflated, venous volume and pressure returned to their max-
imum value and the expelled volume was measured. By use of
individual pressure–volume gradients, the expelled volume was
converted to a pressure decrease. Pressure decrease (P1 ) P2)
was expressed as a percentage of the initial pressure (P1) before
the exercise, and was a measure of the calf muscle pump
function (PF = [P1 ) P2/P1] · 100%) [11].
Venous outflow resistance was assessed by measuring the
maximum venous outflow at five different cuff pressures (60–
20 mmHg). The maximum volume change (DV/V) for each
occlusion pressure was measured, and plotted against the
effective cuff pressure. The slope of the line through the points
gave an angle b. By analogy with Ohms law, venous outflow
resistance was calculated as 1/tangent b and expressed in
resistance units (RU): (mmHg · min)/%.
The study protocol was approved by the institutional review
board, and written informed consent was obtained from all
participants.
Predictors
We selected candidate predictors of PTS on the basis of
previous studies [14–25]. These included sex, age, body mass
index, varicose veins at diagnosis, idiopathic DVT, localization
of DVT, the extent of residual vein thrombosis quantified with
the thrombosis score, the presence of valvular reflux quantified
with the reflux score, calf muscle pump function, and venous
outflow resistance.
Statistical analyses
The cumulative incidence of PTS was calculated as the number
of patients with PTS divided by the overall number of patients.
The relative risk of each predictor was calculated by risk ratios
(RRs), with corresponding 95% confidence intervals (CIs). The
RRs indicate the risk of PTS in the presence of a candidate
predictor relative to the absence of that predictor. The chi-
square test was used to assess differences between proportions.
Subsequently, we included all candidate predictors with a P-
value £ 0.10 in a multivariate logistic regression model. The
ability of the model to discriminate between patients with and
without PTS was estimated by the area under the receiver
operating characteristic (ROC) curve. All computations were
performed with the use of SPSS software, version 14.0 (SPSS,
Chicago, IL, USA).
Results
Patient characteristics of the 111 patients with a first episode of
symptomatic DVT are summarized in Table 1. There were 52
women (47%), the mean age of all patients at the time of
diagnosis was 48 years (5th–95th percentile 27–68 years) and
the overall mean age was 5 years higher in men than in women.
Varicose veins, as assessed by the dermatologist, were present
at entry in 15 patients (13%). Thrombosis was unilateral on the
left side in 55 patients (50%), and none of the patients had
bilateral DVT. Distal thrombosis was present in 18 patients
(16%), andDVTwas idiopathic in 34 patients (31%) (Table 1).
A total of 94 patients (85%) completed 2 years of follow-up,
11 patients did not complete the follow-up because they were
unable to come to the hospital for all examinations, and six
patients died of various causes. Recurrent symptomatic DVT
was diagnosed in six patients. Two recurrences occurred in the
ipsilateral leg and four in the contralateral leg. The median
Table 1 Characteristics of 111 patients with a first episode of deep vein
thrombosis (DVT) of the leg
Characteristic
Women, no. (%) 52 (47)
Age (years), mean (SD) 48 (12)
5th–95th percentile 27–68
BMI (kg m)2), mean (SD) 27 (4)
5th–95th percentile 21–36
Varicose veins at diagnosis, no. (%) 15 (13)
Side of DVT, no. (%)
Left 55 (50)
Right 56 (50)
Localization of DVT, no. (%)
Proximal 73 (66)
Proximal and superficial 13 (12)
Superficial 7 (6)
Distal 18 (16)
Malignancy, no. (%) 6 (5)
Surgery, no. (%) 25 (23)
Plaster cast, no. (%) 9 (8)
Minor injury, no. (%) 34 (31)
Bed rest at home or in hospital, no. (%) 29 (26)
Pregnancy, no. (%) 2 (2)
Hormone use among women, no. (%) 24 (46)
Idiopathic DVT, no. (%) 34 (31)
BMI, body mass index; SD, standard deviation.
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duration to recurrence was 7 months (5th–95th percentile 4–
13 months). Three patients used vitamin K antagonists during
their recurrence.
The mean duration of initial bandage use was 19 days (5th–
95th percentile 8–36 days). Thigh-length compression therapy
was used in 80 of 111 patients (72%) for the first 3 months,
followed by knee-length stockings; the remaining 31 patients
used knee-length compression therapy from diagnosis on-
wards. Elastic therapeutic stockings with compression class III
were used in 107 of 111 patients (96%), and four patients (4%)
used class II stockings. Despite the advice to use elastic
compression stockings for 2 years, 22 patients used them for
a shorter period. In seven of these patients, this was attributable
to intercurrent disease or death, and 15 patients were non-
compliant for other reasons. Good compliance (‡ 6 day-
s week–1) was reported by 74 patients (67%).
Anticoagulation was given for 6 months in 83 patients
(75%); six patients (5%) were treated for a shorter period, with
a mean duration of 95 days (5th–95th percentile 45–128 days).
In 13 of 22 patients who were treated for more than 6 months,
vitamin K antagonist treatment was continued for more than
1 year.
Incidence and severity of PTS
The cumulative incidence of PTS (CEAP ‡ 3) was 46% at
3 months after the DVT and did not increase further (Table 2).
The incidence of CEAP classification 4 progressed from 26%
at entry to 33% at 6 weeks and then also stabilized, at 38%
after 3 months. The initial increase in CEAP classification 4
skin changes was mainly attributable to newly formed corona
phlebectatica. None of the patients was diagnosed with CEAP
classification 5 or 6. PTS was established in the first 3 months
after DVT, without progression of the incidence or severity in
the second year.
Residual thrombosis and valvular reflux
In all veins, thrombus resolution was a continuing process. The
resolution of thrombus was more rapid and complete in
patients with thrombosis in distal vein segments than in those
with proximal thrombosis. At diagnosis, 78% of the five
proximal vein segments were occluded completely or in part;
after 6 weeks, this was reduced to 54%, and after 2 years, 33%
showed residual thrombosis (Table 3). The superficial and
distal vein segments showed less residual thrombosis after
2 years: 7% and 3%, respectively. Men had more proximal
residual thrombosis at 6 weeks than women; 35 of 55 men
(64%), as compared with 20 of 47 women (43%). The
thrombosis score declined from a mean of 3.8 non-compress-
ible segments at diagnosis to 2.0 after 6 weeks and 0.8 after
2 years. Valvular reflux was present at an average of 0.6
segments at diagnosis, and this increased slightly to 0.9
segments after 6 weeks and 1.1 after 2 years.
Functional venous hemodynamic tests
At diagnosis, 22% of patients had calf muscle pump function
below 40%; 6 weeks later, this was only 13%, and the
proportion declined to 6% after 1 and 2 years (Table 4). Only
Table 2 Clinical, Etiologic, Anatomic, and Pathophysiologic (CEAP) score during follow-up in 111 patients with a first episode of deep vein thrombosis in
the leg
CEAP score Clinical signs Diagnosis 6 weeks 3 months 6 months 1 year 2 years*
0 No visible or palpable signs 25 44 42 42 39 42
1–2 Telangiectases, reticular veins, malleolar
flare or varicose veins
6 10 12 10 12 14
3 Edema, without skin changes 43 13 8 7 10 5
4 Skin changes ascribed to venous disease 26 33 38 41 39 39
5–6 Skin changes with (healed) ulceration 0 0 0 0 0 0
‡ 3 Post-thrombotic syndrome 46 46 48 49 44
All values are percentages of all patients, i.e. 25 means that 25% of all patients had a CEAP score of zero at diagnosis. *In 13 patients, CEAP was
incomplete during 2 years of follow-up.
Table 3 Residual thrombosis and valvular reflux over time in patients with a first episode of deep vein thrombosis
Vein segments
Residual thrombosis Valvular reflux
Diagnosis
n = 111
6 weeks
n = 102
2 years
n = 97
Diagnosis
n = 72
6 weeks
n = 102
2 years
n = 97
Proximal, n (%) (five vein segments) 87 (78) 55 (54) 32 (33) 6 (8) 21 (21) 36 (37)
Superficial, n (%) (four vein segments) 20 (18) 17 (17) 2 (7) 9 (13) 22 (22) 15 (16)
Distal, n (%) (eight vein segments) 69 (62) 29 (28) 3 (3) 5 (7) 0 (0) 7 (7)
Thrombosis score Reflux score, mean* (range) 3.8 (0–11) 2.0 (0–9) 0.8 (0–5) 0.6 (0–5) 0.9 (0–7) 1.1 (0–7)
*Mean score of 17 vein segments.
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20% of patients had calf muscle pump function > 60% at
diagnosis; this proportion increased to 38% after 6 weeks, and
then stabilized at 40% after 1 and 2 years. Mean calf muscle
pump function improved from 48% at diagnosis to 54% after
6 weeks, and was stable at 56% at 1 and 2 years.
Mean venous outflow resistance declined during treatment
from 3.0 RU at diagnosis to 2.5 RU after 3 months, remained
stable during 1 year of follow-up, and showed an increase to
2.9 RU after 2 years of follow-up.
Predictors of PTS
Men had a 1.4-fold higher risk of developing PTS 1 year after
DVT than women (RR 1.4, 95% CI 0.9–2.2) (Table 5).
Patients aged over 50 years had a 1.4-fold increased risk of
PTS as compared with patients below this age (RR 1.4%,
95% CI 0.9–2.1). The risk of PTS was 2.3-fold higher in
patients with thrombosis localized in the proximal veins than in
those with distal thrombosis (RR 2.3%, 95% CI 1.0–5.6). PTS
developed in 39 of 64 patients (61%) with residual thrombosis,
i.e. thrombosis score ‡ 1, 6 weeks after diagnosis, as compared
with 10 of 33 patients (30%) without residual thrombosis,
leading to a two-fold increased risk (RR 2.0%, 95% CI 1.6–
3.5). Patients with residual thrombosis in the proximal veins,
i.e. proximal thrombosis score ‡ 1, also had an increased risk as
compared with patients without proximal residual thrombosis
(RR 1.6%, 95% CI 1.0–2.5). The presence of valvular reflux in
one or more vein segments 6 weeks after diagnosis, i.e. reflux
score ‡ 1, as compared with no reflux showed a 1.5-fold
increased risk of PTS (RR 1.5%, 95% CI 1.0–2.2). PTS
developed in 13 of 18 patients (72%) with superficial valvular
reflux 6 weeks after diagnosis, as compared with 36 of 79
patients (46%) without superficial reflux. The presence of
superficial valvular reflux was a predictor of PTS, with a 1.6-
fold increased risk as compared with patients without super-
ficial reflux (RR 1.6%, 95% CI 1.1–2.3). The combination of
residual thrombosis in the proximal veins and the presence of
superficial valvular reflux was seen in eight patients, seven of
whom developed PTS (88%) at 1 year.
Body mass index, varicose veins at diagnosis and idiopathic
DVT were not associated with the development of PTS, and
nor were calf muscle pump function and venous outflow
resistance.
Sex, age, localization of DVT, (proximal) thrombosis score
at 6 weeks, reflux score and the presence of superficial valvular
reflux at 6 weeks were associated (all P-values £ 0.1) with the
development of PTS. Proximal thrombosis score and superfi-
cial valvular reflux were included in a multivariate model
Table 4 Calf muscle pump and venous outflow resistance measured by strain gauge plethysmography during 2 years of follow-up
Diagnosis 6 weeks 3 months 6 months 1 year 2 years*
CMP < 40%, n (%) 22 (22) 13 (13) 13 (13) 11 (11) 6 (6) 6 (6)
CMP 40–60%, n (%) 59 (58) 50 (49) 41 (41) 43 (42) 51 (54) 51 (54)
CMP ‡ 60%, n (%) 20 (20) 38 (38) 47 (46) 48 (47) 37 (40) 37 (40)
CMP (%), mean (range) 48 (10–76) 54 (14–79) 55 (10–80) 56 (20–76) 56 (23–80) 56 (24–94)
VOR (RU), mean (range) 3.0 (0.6–17.2) 2.9 (0.3–25.0) 2.5 (0.7–19.3) 2.5 (0.6–9.2) 2.5 (0.4–13.2) 2.9 (0.7–16.1)
CMP, calf muscle pump function; VOR, venous outflow resistance; RU, resistance unit. *In 17 patients, strain gauge plethysmography was not
complete during 2 years of follow-up.
Table 5 Risk of post-thrombotic syndrome (PTS) 1 year after deep vein
thrombosis (DVT) in 99 patients
With PTS
N = 49
N (%)
Without PTS
N = 50
N (%)
Risk ratio
(95% CI)
Sex
Men 30 (58) 22 (42) 1.4 (0.9–2.2)
Women 19 (40) 28 (60)
Age (years)
‡ 50 24 (59) 17 (41) 1.4 (0.9–2.1)
< 50 25 (43) 33 (57)
BMI (kg m)2)
‡25 33 (51) 32 (49) 1.1 (0.7–1.7)
< 25 16 (47) 18 (53)
Varicose veins at diagnosis
Yes 8 (62) 5 (38) 1.3 (0.8–2.1)
No 41 (48) 45 (52)
Idiopathic DVT
Yes 14 (45) 17 (55) 0.9 (0.5–1.4)
No 35 (51) 33 (49)
DVT localization
Proximal 45 (55) 37 (45) 2.3 (1.0–5.6)
Distal 4 (23) 13 (77)
TS at 6 weeks*
‡ 1 39 (61) 25 (39) 2.0 (1.6–3.5)
< 1 10 (30) 23 (70)
TSproximal at 6 weeks*
‡ 1 32 (62) 20 (38) 1.6 (1.1–2.5)
< 1 17 (38) 28 (62)
Reflux score at 6 weeks*
‡ 1 19 (66) 10 (34) 1.5 (1.0–2.2)
< 1 30 (44) 38 (56)
Superficial reflux at 6 weeks*
Yes 13 (72) 5 (28) 1.6 (1.1–2.3)
No 36 (46) 43 (54)
Popliteal reflux at 6 weeks*
Yes 8 (67) 4 (33) 1.4 (0.9–2.2)
No 41 (48) 44 (52)
CMP at 6 weeks*
< 60% 33 (57) 25 (43) 1.3 (0.8–2.0)
‡ 60% 16 (44) 20 (56)
VOR at 6 weeks*
‡ 1.5 RU 38 (53) 34 (47) 1.1 (0.7–1.7)
< 1.5 RU 11 (50) 11 (50)
BMI, body mass index; CI, confidence interval; CMP, calf muscle
pump function; RU, resistance units; TS, thrombosis score; VOR,
venous outflow resistance. *Unknown in £ 5 patients.
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together with sex, age, and localization. This model yielded an
area under the ROC curve of 0.72 (95% CI 0.62–0.82).
Subsequent addition of venous outflow resistance and calf
muscle pump function to this model resulted in a minor
improvement, with an area under the ROC curve of 0.75
(95% CI 0.66–0.85). Replacement of proximal thrombosis
score with overall thrombosis score and superficial valvular
reflux with overall reflux score led to an area under the ROC
curve of 0.77 (95% CI 0.68–0.87). Subsequent addition of
idiopathic thrombosis showed the highest area under the ROC
curve of 0.79 (95% CI 0.70–0.88). Addition of body mass
index or varicose veins at diagnosis did not show further
improvement of the area under the ROC curve.
Discussion
This study revealed that PTS occurs in half of all patients
within 3 months after a first episode of symptomatic DVT of
the leg when elastic compression stockings are applied. Non-
invasive venous examination 6 weeks after diagnosis showed
that residual thrombosis of the proximal veins and valvular
reflux in the superficial veins were predictors of PTS. Other
predictors included proximal localization of thrombosis at
diagnosis, age over 50 years, and male sex.
Residual thrombosis and valvular reflux were measured with
duplex examination in 17 vein segments of the leg, which is an
elaborate examination, even in the hands of experienced
vascular technicians. Both proximal thrombosis score, which
quantifies the occlusion of five proximal vein segments, and
superficial reflux score, which quantifies valvular reflux in the
four superficial vein segments, were predictors of PTS. Previous
studies showed that (proximal) thrombosis score and (super-
ficial) reflux score, measured 3–6 months after diagnosis, are
predictors of PTS [15,16,18,20]. Here, we have shown the
predictive value of a simplified duplex examination as early as
6 weeks after DVT.
Proximal localization of thrombosis at diagnosis showed an
increased risk of PTS. The results of previous studies have been
inconsistent with regard to the relationship between localiza-
tion of the initial thrombus and subsequent development of
PTS [7,21,24,25,27]. An explanation for the increased risk of
PTSmay be that patients with proximal thrombosis have more
residual thrombosis, and residual thrombosis increases the risk
of PTS. Another possible explanation is that the collateral
circulation in the proximal veins is less extensive than that in
the distal veins of the calf, as each artery in the calf is
accompanied by two veins.
We found that older age and male sex appear to confer an
increased risk of developing PTS. The increased risk in elderly
patients has been reported in some studies [8,21,23,25], but not
all [19,22,24]. Hypercoagulability and advanced sclerotic
changes in the vascular wall may contribute to the increased
risk in the elderly [28]. Male sex was a risk factor in one other
study [21], in contrast to the findings of recent reports [23–25].
The higher risk of PTS in men might be related to the older age
of men in this study and the higher rate of proximal residual
thrombosis. The reason why men might have delayed throm-
bus regression is currently unknown, but explains their higher
risk of recurrent thrombosis [17,29–31]. Overall, the predictive
values of age and sex were not consistent in previous studies.
In contrast to other studies, body mass index was not
associated with the development of PTS in our study [19,21–
24]. Furthermore, we did not show a predictive value of the
non-invasive examination of calf muscle pump function and
venous outflow resistance in the univariate analysis. Addition
of these tests to the multivariate model gave only a minor
improvement in the area under the ROC curve. This is in
contrast to previous studies that identified venous outflow
resistance as a predictor of PTS [15,20].
The overall 49% risk of PTS that we observed after 1 year is
comparable with the incidence of PTS after 1–2 years found in
other studies that used the CEAP classification [15,16,20,21].
Studies that used theVillalta scale to classify PTS found a lower
incidence of 20–40% [7,9,18,22–25]. The Villalta scale uses
symptoms and signs, whereas the CEAP classification uses
clinical signs that represent a progressive gradation of disease
severity. A higher incidence of PTS with use of the CEAP score
than with use of the Villalta scale was also shown in a study
that compared the different classifications for PTS [32]. As a
wide variety of definitions of PTS have been used, the ability to
compare results from different studies will remain limited. The
decision to use the CEAP classification rather than the Villalta
scale for definition of PTS was taken far in advance of the
recommendation for standardization delivered by the Scientific
and Standardization Committee of the ISTH [33].
None of the patients in our study had a CEAP classification
of 5 or 6. The use of immediate short-stretch elastic bandages
followed by class III elastic therapeutic stockings probably
reduced the development of PTS, and may be the explanation
for the absence of venous ulceration [8,9,20,34].
The true time of onset of PTS after an objectively diagnosed
first DVT is uncertain. Earlier studies, one with a follow-up of
20 years, suggested a gradual increase in incidence of PTS over
the years [7,34,35]. More recent studies with a follow-up period
of 5 years showed that PTS develops within 2 years
[8,9,20,25,36]. Our results show that PTS is established within
3 months after DVT, without an increase in the incidence or
severity of PTS after 1–2 years, in patients treated with
immediate adequate compression therapy.
A possible clinical implication of our findings is that
simplified duplex scanning should be performed in all patients
6 weeks after DVT to identify patients at high risk for PTS.
This syndrome developed within 1 year in 88%of patients with
combined residual proximal thrombosis and superficial valvu-
lar reflux.
Another important reason to implement non-invasive
examination with duplex scanning 6 weeks after diagnosis is
to differentiate between symptomatic recurrent thrombosis and
residual thrombosis with post-thrombotic complaints during
follow-up. Patients with recurrent thrombosis should be treated
with anticoagulation therapy, whereas compression therapy is
the treatment strategy in patients with residual thrombosis and
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post-thrombotic complications. Patients with residual throm-
bus have an increased risk of both recurrence and PTS
[15,17,18,20,37]. Duplex scanning 6 weeks after diagnosis
elucidates the changes of the thrombus in the individual
patient, and enables the physician to compare residual
thrombus with recurrent thrombus when a patient returns
with symptoms after a DVT.
The results of this study may have implications for the
advisable duration of elastic compression stocking use. We
found that men over 50 years of age with proximal DVT and
residual proximal thrombosis or superficial valvular reflux
6 weeks after diagnosis were at increased risk of developing
PTS. These high-risk patients are candidates for long-term
compression therapy. A question that remains to be answered
is how long patients with an indication for long-term
compression therapy should continue with this therapy:
2 years, or even longer. In patients without these predictors
or signs of PTS, compression therapy could be stopped after
adequate treatment and recovery from DVT in the first 3–
6 months. Prospective studies should confirm whether it is safe
to withhold compression therapy in these patients.
Our study has some limitations. First, it has a relatively small
sample size. Nevertheless, we were able to identify predictors
for PTS. Confirmation by other studies is needed. Second, 17
(15%) patients did not fully complete 2 years of follow-up; six
(5%) of these patients died.
We conclude that PTS develops in half of all patients within
3 months, with no increase in incidence or severity up to
2 years of follow-up. Male sex, age over 50 years, proximal
localization of thrombus at diagnosis, residual thrombosis in
the proximal veins and valvular reflux in the superficial veins
6 weeks after diagnosis are predictors of the development of
PTS in patients with a first episode of DVT. Simplified duplex
scanning 6 weeks after diagnosis of DVT enables the identi-
fication of patients at high risk of PTS.
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